Rosenstock J, Wysham C, Frias JP, Kaneko S, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 2021 Jun 25. pii: S0140-6736(21)01324.
PMID: 34186022